Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

Products from BPS Bioscience require a minimum order value above 400€

Applications: Screen or titrate neutralizing antibodies against SARS-CoV-2 Spike Omicron XBB.1.16 variant in ACE2-expressing cells.

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. The Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread easier and quicker than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of April 2023, additional new sub-lineages (BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5, XBB.1.16) have been identified.

Description: The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain firefly luciferase driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by luciferase activity. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudoviruses can be used to measure the activity of a neutralizing antibody against the SARS-CoV-2 Omicron XBB.1.16 variant.The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; >BPS Bioscience #79951).

Formulation: The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Supplied As: The titer will vary with each lot; the exact value is provided with each shipment. Based on experiments performed by scientists at BPS Bioscience, 78784-1 (100 µl) provides sufficient signal-to-noise ratio to perform 100 reactions, and 78784-2 (500 µl x 2) for 1000 reactions. The amount of virus added to the cells can be titrated further down according to the user's need.

Warnings: Avoid freeze/thaw cycles

Biosafety Level: BSL-2

• Artikelnummer: BPS78784-2
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 78784-2
• Verpackungseinheit: 500 µl x 2
• Mengeneinheit: STK